BS

Biji Sivalayamgirija

Active Director Director DIN 11113354
DIN 11113354 First appointment May 2025 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since May 2025
Shareholding value β€’β€’β€’β€’ Premium profile

About Biji Sivalayamgirija

Data last updated:

Biji Sivalayamgirija is a Director at Life Care Super Speciality Pharma Private Limited (since 2025). The company operates in Pharma.

DIN 11113354
Primary Designation Director
Industry Pharma
First Appointment 19 May 2025
Oldest Company Age 1 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director19 May 20252025Active

Board colleagues of Biji Sivalayamgirija

NameDINCompanyDesignation
Venugopalan Balagopal11113353Life Care Super Speciality Pharma Private LimitedManaging Director

Directorship timeline

Open interactive timeline →
Life Care Super Speciality Pharma Private Limited
Premium access

Shareholding and investment profile for Biji Sivalayamgirija

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Biji Sivalayamgirija

Biji Sivalayamgirija currently holds 1 directorship: Life Care Super Speciality Pharma Private Limited (Director, since 19 May 2025).

Biji Sivalayamgirija was first appointed on 19 May 2025 as Director at Life Care Super Speciality Pharma Private Limited.

The current boards of Biji Sivalayamgirija's companies include Venugopalan Balagopal (Life Care Super Speciality Pharma Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available